StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion

Hanna,Samer; Khalil,Bassem; Nasrallah,Anita; Saykali,Bechara A.; Sobh,Rania; Nasser,Selim; El-Sibai,Mirvat

doi:10.3892/ijo.2014.2330

StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion

Authors:
- Samer Hanna
- Bassem Khalil
- Anita Nasrallah
- Bechara A. Saykali
- Rania Sobh
- Selim Nasser
- Mirvat El-Sibai
View Affiliations

Affiliations: Department of Natural Sciences, The Lebanese American University, Beirut 1102 2801, Lebanon, School of Medicine, The Lebanese American University, Beirut 1102 2801, Lebanon
Published online on: March 7, 2014 https://doi.org/10.3892/ijo.2014.2330
Pages: 1499-1511
Copyright: © Hanna et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most commonly diagnosed cancers in women around the world. In general, the more aggressive the tumor, the more rapidly it grows and the more likely it metastasizes. Members of the Rho subfamily of small GTP-binding proteins (GTPases) play a central role in breast cancer cell motility and metastasis. The switch between active GTP-bound and inactive GDP-bound state is regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and guanine-nucleotide dissociation inhibitors (GDIs). We studied the role of StarD13, a recently identified Rho-GAP that specifically inhibits the function of RhoA and Cdc42. We aimed to investigate its role in breast cancer proliferation and metastasis. The levels of expression of this Rho-GAP in tumor tissues of different grades were assayed using immunohistochemistry. We observed that, while the level of StarD13 expression decreases in cancer tissues compared to normal tissues, it increases as the grade of the tumor increased. This was consistent with the fact that although StarD13 was indeed a tumor suppressor in our breast cancer cells, as seen by its effect on cell proliferation, it was needed for cancer cell motility. In fact, StarD13 knockdown resulted in an inhibition of cell motility and cells were not able to detach their tail and move forward. Our study describes, for the first time, a tumor suppressor that plays a positive role in cancer motility.

View Figures

View References

1.	Jiang P, Enomoto A and Takahashi M: Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett. 284:122–130. 2009. View Article : Google Scholar
2.	Claus EB, Stowe M and Carter D: Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst. 93:1811–1817. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Bombonati A and Sgroi DC: The molecular pathology of breast cancer progression. J Pathol. 223:307–317. 2011. View Article : Google Scholar
4.	van Golen KL: Inflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancers. Breast Cancer Res. 5:174–179. 2003.PubMed/NCBI
5.	Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar
6.	Tang Y, Olufemi L, Wang MT and Nie D: Role of Rho GTPases in breast cancer. Front Biosci. 13:759–776. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Etienne-Manneville S and Hall A: Rho GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar
8.	Vega FM and Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Takai Y, Sasaki T and Matozaki T: Small GTP-binding proteins. Physiol Rev. 81:153–208. 2001.PubMed/NCBI
10.	Moon SY and Zheng Y: Rho GTPase-activating proteins in cell regulation. Trends Cell Biol. 13:13–22. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Grise F, Bidaud A and Moreau V: Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta. 1795:137–151. 2009.PubMed/NCBI
12.	Ching YP, Wong CM, Chan SF, et al: Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem. 278:10824–10830. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Ullmannova V and Popescu NC: Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol. 29:1127–1132. 2006.
14.	Thorsell AG, Lee WH, Persson C, et al: Comparative structural analysis of lipid binding START domains. PLoS One. 6:e195212011. View Article : Google Scholar : PubMed/NCBI
15.	Liao YC and Lo SH: Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol. 40:843–847. 2008. View Article : Google Scholar : PubMed/NCBI
16.	El-Sitt S, Khalil BD, Hanna S, El-Sabban M, Fakhreddine N and El-Sibai M: DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma. Oncol Rep. 28:511–518. 2012.PubMed/NCBI
17.	Nobes CD and Hall A: Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol. 144:1235–1244. 1999. View Article : Google Scholar : PubMed/NCBI
18.	Wolfenson H, Henis YI, Geiger B and Bershadsky AD: The heel and toe of the cell’s foot: a multifaceted approach for understanding the structure and dynamics of focal adhesions. Cell Motil Cytoskeleton. 66:1017–1029. 2009.
19.	Arjonen A, Kaukonen R and Ivaska J: Filopodia and adhesion in cancer cell motility. Cell Adh Migr. 5:421–430. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Sander EE, ten Klooster JP, van Delft S, van der Kammen RA and Collard JG: Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol. 147:1009–1022. 1999. View Article : Google Scholar
21.	Cox EA, Sastry SK and Huttenlocher A: Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases. Mol Biol Cell. 12:265–277. 2001. View Article : Google Scholar : PubMed/NCBI
22.	Kaverina I, Krylyshkina O and Small JV: Regulation of substrate adhesion dynamics during cell motility. Int J Biochem Cell Biol. 34:746–761. 2002. View Article : Google Scholar : PubMed/NCBI
23.	El-Sibai M, Pertz O, Pang H, et al: RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependent protrusion in MTLn3 carcinoma cells. Exp Cell Res. 314:1540–1552. 2008. View Article : Google Scholar
24.	Banyard J, Anand-Apte B, Symons M and Zetter BR: Motility and invasion are differentially modulated by Rho family GTPases. Oncogene. 19:580–591. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Vial E, Sahai E and Marshall CJ: ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Tkach V, Bock E and Berezin V: The role of RhoA in the regulation of cell morphology and motility. Cell Motil Cytoskeleton. 61:21–33. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and Popescu NC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58:2196–2199. 1998.
28.	Yuan BZ, Durkin ME and Popescu NC: Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet. 140:113–117. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Durkin ME, Yuan BZ, Zhou X, et al: DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med. 11:1185–1207. 2007. View Article : Google Scholar : PubMed/NCBI
30.	Yuan BZ, Zhou X, Durkin ME, et al: DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene. 22:445–450. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Ng IO, Liang ZD, Cao L and Lee TK: DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res. 60:6581–6584. 2000.PubMed/NCBI
32.	Kim TY, Vigil D, Der CJ and Juliano RL: Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 28:77–83. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Zhong D, Zhang J, Yang S, et al: The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci. 122:414–424. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Shih YP, Takada Y and Lo SH: Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells. Mol Cancer Res. 10:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
35.	Cao X, Voss C, Zhao B, Kaneko T and Li SS: Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation. Proc Natl Acad Sci USA. 109:1455–1460. 2012. View Article : Google Scholar : PubMed/NCBI
36.	Massague J: TGFbeta in Cancer. Cell. 134:215–230. 2008. View Article : Google Scholar
37.	Wang Y and McNiven MA: Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol. 196:375–385. 2012. View Article : Google Scholar : PubMed/NCBI
38.	Pille JY, Denoyelle C, Varet J, et al: Anti-RhoA and anti-Rh˚C siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther. 11:267–274. 2005.PubMed/NCBI
39.	Wu M, Wu ZF, Rosenthal DT, Rhee EM and Merajver SD: Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer. 116:2768–2782. 2010. View Article : Google Scholar : PubMed/NCBI
40.	Sahai E and Marshall CJ: Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 5:711–719. 2003. View Article : Google Scholar : PubMed/NCBI